导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.42% | 2611/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -5.28% | 3146/5421 |
| 近一季 | -7.78% | 2531/5209 |
| 近半年 | -2.99% | 2088/4920 |
| 近一年 | 2.31% | 2147/4366 |
| 近两年 | 46.75% | 1581/2954 |
| 近三年 | 31.15% | 1009/2253 |
| 成立以来 | 176.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.23% 3083/4961 |
13.44% 2003/5312 |
- - |
- - |
| 2025 | 22.27% 1981/4813 |
0.04% 1999/3635 |
1.14% 2452/4076 |
20.46% 1980/4524 |
0.32% 2060/4813 |
| 2024 | 16.63% 787/3463 |
2.98% 645/2808 |
-0.81% 844/3014 |
16.35% 1480/3129 |
-1.86% 1869/3463 |
| 2023 | -7.93% 963/2656 |
4.59% 914/2280 |
-3.80% 907/2385 |
-2.44% 678/2515 |
-6.22% 1677/2655 |
| 2022 | -18.47% 713/2207 |
-12.55% 631/1919 |
6.88% 586/2016 |
-13.91% 993/2113 |
1.33% 1300/2208 |
| 2021 | -2.27% 844/1822 |
-1.46% 496/1255 |
3.03% 983/1330 |
-5.40% 803/1466 |
1.76% 804/1822 |
| 2020 | 37.76% 375/1250 |
-9.30% 669/1028 |
12.70% 673/1067 |
16.79% 132/1164 |
15.38% 211/1184 |
| 2019 | 38.36% 310/1092 |
23.56% 547/754 |
2.77% 70/804 |
2.12% 321/850 |
6.70% 568/918 |
| 2018 | -22.11% 230/834 |
- - |
- - |
- - |
-11.53% 310/691 |
| 2017 | 0.84% 466/714 |
- - |
- - |
- - |
- - |
| 2016 | 3.40% 81/605 |
- - |
- - |
- - |
- - |
| 2015 | 22.28% 105/575 |
- - |
- - |
- - |
- - |
| 2014 | 9.50% 209/237 |
- - |
- - |
- - |
- - |
| 2013 | 2.34% 64/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.80% 91/140 |
- - |
- - |
- - |
- - |
| 2011 | -7.97% 4/4 |
- - |
- - |
- - |
- - |
| 2010 | 12.27% 1/4 |
- - |
- - |
- - |
- - |
| 2009 | 13.47% 2/4 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方中证A100指数A VS. 长安沪深300非周期A(740101) |